

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

09/269.903

Filing Date

May 6, 1999

First Named Inventor

Peter James Watts

Group Art Unit

~~1645~~ 1616

Examiner Name

Reuben V. Williams

Attorney Docket Number

WC 131

U.S. PATENT DOCUMENTS

[illegible]

**Examine
Signature**

Carl V. Wilkin

Date Considered

10 January 2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/269,903 |
| Filing Date | May 6, 1999 |
| First Named Inventor | Peter James Watts |
| Group Art Unit | 1615 1616 |
| Examiner Name | Perrelli V. Williams |
| Attorney Docket Number | WC 131 |



Sheet 2 of 4

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM- DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|-----------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|---|---|----------------|
| | | Office. ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| <i>P.J.W.</i> | | DE | 42 36 025 | A1 | Merck Patent GmbH | 04-28-1994 | | |
| <i>P.J.W.</i> | | GB | 2 166 051 | A | Alza Corp. | 04-30-1986 | | |
| <i>P.J.W.</i> | | GB | 2 174 599 | A | Norwich Eaton Pharmaceuticals Inc. | 11-12-1986 | | |
| <i>P.J.W.</i> | | GB | 2 238 243 | A | National Research Development Corp. | 05-29-1991 | | |
| <i>P.J.W.</i> | | EP | 0 221 601 | A1 | Janssen Pharmaceutica N.V. | 05-13-1987 | | |
| <i>P.J.W.</i> | | EP | 0 338 383 | A2 | Schwarz Pharma AG | 10-25-1989 | | |
| <i>P.J.W.</i> | | EP | 0 365 947 | A1 | Pharmacia AB | 05-02-1990 | | |
| <i>P.J.W.</i> | | EP | 0 513 035 | B1 | Danbiosyst UK Ltd. | 10-20-1993 | | |
| <i>P.J.W.</i> | | EP | 0 519 870 | A1 | Spirig AG-Pharmazeutische Präparate | 12-23-1992 | | |
| <i>P.J.W.</i> | | EP | 0 572 942 | A2 | Poli Industria Chimica S.p.A. | 12-08-1993 | | |
| <i>P.J.W.</i> | | EP | 0 621 032 | A1 | Ciba-Geigy AG | 10-26-1994 | | |
| <i>P.J.W.</i> | | EP | 0 640 337 | A2 | SS Pharmaceutical Co. Ltd. | 03-01-1995 | | |
| <i>P.J.W.</i> | | EP | 0 673 645 | A2 | F. Hoffmann-La Roche AG | 09-27-1995 | | |
| <i>P.J.W.</i> | | WO | 89/11269 | A1 | Agricultural and Food Research Council | 11-30-1989 | | |
| <i>P.J.W.</i> | | WO | 90/13286 | A1 | Chugai-Seiyaku-Kabushiki Kaisha | 11-15-1990 | | |
| <i>P.J.W.</i> | | WO | 91/16881 | A1 | Development Company of the Hebrew University of Jerusalem | 11-14-1991 | | |
| <i>P.J.W.</i> | | WO | 92/01457 | A1 | Rhodes, et al. | 02-06-1992 | | |
| <i>P.J.W.</i> | | WO | 92/14452 | A1 | Rhodes, et al. | 09-03-1992 | | |
| <i>P.J.W.</i> | | WO | 95/06464 | A1 | Galenik Labor Freiburg GMBH | 03-09-1995 | | |
| <i>P.J.W.</i> | | WO | 95/14037 | A1 | Ibah, Inc. | 05-26-1995 | | |
| <i>P.J.W.</i> | | WO | 95/35100 | A1 | Danbiosyst UK Ltd. | 12-28-1995 | | |
| <i>P.J.W.</i> | | WO | 96/30016 | A2 | Janssen Pharmaceutica N.V. | 10-03-1996 | | |

| | | | |
|----------------------|-----------------------------|-----------------|-------------|
| Examine Signature | <i>Perrelli V. Williams</i> | Date Considered | 10 Jan 2000 |
|----------------------|-----------------------------|-----------------|-------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 09/269,903 |
| Filing Date | May 6, 1999 |
| First Named Inventor | Peter James Watts |
| Group Art Unit | 1615 1616 |
| Examiner Name | Pernell V. Williams |
| Attorney Docket Number | WC 131 |

Sheet 3 of 4

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|----------------------|-----------------------|--|----------------|
| P.V.W. | | ASHFORD, et al., "In Vivo Assessment of Colonic Drug Delivery Systems," <i>Br. Pharm. Conference Abstract</i> 13, p. 1049 (1992). | |
| P.V.W. | | BURNS, et al., "An in vitro assessment of liquid-filled Capill [®] potato starch capsules with biphasic release characteristics," <i>Int. J. Pharm.</i> 134:223-30 (1996). | |
| P.V.W. | | HEALEY, "Enteric Coatings and Delayed Release" in <i>Drug Delivery to the Gastrointestinal Tract</i> (Hardy, et al., eds.) Ellis Horwood:Chichester, 1989. | |
| P.V.W. | | KENYON, et al., "The effect of food on the in vivo behaviour of enteric coated starch capsules," <i>Int. J. Pharm.</i> 112:207-13 (1994). | |
| P.V.W. | | KOPE EK, et al., "Polymers for colon-specific drug delivery," <i>J. Control. Rel.</i> 19:121-30 (1992). | |
| P.V.W. | | MILOJEVIC, et al., "In Vitro and In Vivo evaluation of amylose coated pellets for colon specific drug delivery," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> 20:288-89 (1993). | |
| P.V.W. | | RUBINSTEIN & GLIKO-KABIR "Synthesis and swelling-dependent enzymatic degradation of borax-modified guar gum for colonic delivery purposes," <i>S.T.P. Pharma Sciences</i> 5:41-46 (1995). | |
| P.V.W. | | RUBINSTEIN, et al., "Colonic Drug Delivery: Enhanced Release of Indomethacin from Cross-Linked Chondroitin Matrix in Rat Cecal Content," <i>Pharm. Res.</i> 9(2):276-78 (1992). | |
| P.V.W. | | RUBINSTEIN, et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Drug Delivery Carrier," <i>Pharm. Res.</i> 10(2):258-63 (1993). | |
| P.V.W. | | SIEFKE, et al., "Colon Targeting with β -CD Matrix Films," <i>Eur. J. Pharm. Biopharm.</i> 40 (suppl.):33S (1994). | |

| | | | |
|----------------------|---------------------|-----------------|-----------------|
| Examiner's Signature | Pernell V. Williams | Date Considered | 10 January 2000 |
|----------------------|---------------------|-----------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--------|----------------------|---------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/269,903 |
| | | Filing Date | May 6, 1999 |
| | | First Named Inventor | Peter James Watts |
| | | Group Art Unit | 1615 1616 |
| | | Examiner Name | Perrell V. Williams |
| Attorney Docket Number | WC 131 | | |

| OTHER ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| <i>PJW</i> | | THE UNITED STATES PHARMACOPOEIA, USP23, pp. 1791-93 (1994). | |
| <i>PJW</i> | | VAN DEN MOOTER, "Azo polymers for colon-specific drug delivery," <i>Int. J. Pharm.</i> 87:37-46 (1992). | |
| <i>PJW</i> | | WILDING, et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation," <i>Pharm. Res.</i> 9(5):654-57 (1992). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-------------------------|----------------------------|-----------------|-----------------|
| Examiner's Signature | <i>Perrell V. Williams</i> | Date Considered | 10 January 2000 |
|-------------------------|----------------------------|-----------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.